Home > Boards > US Listed > Medical - Healthcare > TransEnterix Inc. (TRXC)

The correction has run a bit deep, and

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
investora2z Member Profile
 
Followed By 9
Posts 602
Boards Moderated 0
Alias Born 02/08/13
160x600 placeholder
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 11/6/2020 6:07:14 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2020 4:36:13 PM
TransEnterix, Inc. Reports Operating and Financial Results for the Third Quarter 2020 Business Wire - 11/5/2020 4:05:00 PM
TransEnterix to Present at the Stifel 2020 Virtual Healthcare Conference Business Wire - 11/3/2020 6:55:00 AM
TransEnterix Schedules Third Quarter Financial and Operating Results Conference Call for November 5, 2020 Business Wire - 10/26/2020 6:55:00 AM
TransEnterix Announces First Pediatric Surgical Cases with Senhance® Surgical System Business Wire - 10/13/2020 6:55:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 10/9/2020 5:26:49 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/9/2020 5:05:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/8/2020 4:31:26 PM
TransEnterix Announces Toshima Hospital in Japan to Initiate a Senhance® Digital Laparoscopy Program Business Wire - 10/7/2020 6:55:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2020 5:40:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2020 5:38:33 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2020 5:37:16 PM
TransEnterix Ushers in New Era of Robotic Surgery with First Usage of Machine Vision Capabilities Business Wire - 9/23/2020 6:55:00 AM
トランスエンテリックスがSenhance手術システムの日本における研修センター設立を発表 Business Wire - 9/16/2020 7:01:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/15/2020 2:46:31 PM
TransEnterix Announces Establishment of Japanese Training Center for Senhance Surgical System Business Wire - 9/14/2020 6:55:00 AM
TransEnterix to Present at the H. C. Wainwright 22nd Annual Global Investment Conference Business Wire - 9/8/2020 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/25/2020 7:07:03 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/25/2020 7:04:57 PM
TransEnterix Announces New Employment Inducement Grant Business Wire - 8/25/2020 6:15:00 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 8/14/2020 4:34:06 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/13/2020 4:32:06 PM
TransEnterix Announces Appointment of Shameze Rampertab as Chief Financial Officer Business Wire - 8/13/2020 6:55:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/10/2020 6:06:38 AM
investora2z   Wednesday, 10/09/13 06:52:49 AM
Re: None
Post # of 7717 
The correction has run a bit deep, and the stock is now down 19% over the last one month. It is down 24% from the 52 week high made in August. However, despite the correction it has delivered great returns and has appreciated by 385% on a ytd basis. The merger with TransEnterix has changed the sentiments for the company. Synergies are expected between the two companies, and the combined entity is financially in a better position. The funding obtained by SafeStitch will help provide the resources required for development and commercialization of its products, especially SurgiBot surgical robotic system. The company got $30.2 million funding through private placement of equity, with TransEnterix contributing 65%, and Dr. Frost and other investors contributing 35%. The huge investment by Dr. Frost and his joining the board of TransEnterix is also a major reason for investor interest in the stock. The investment indicates the faith in the future prospects of the combined entity. Frost's investments in the pharma / biotechnology sector are well known, and his recent investment in Biozone (BZNE) is also promising. Biozone owns the high potential proprietary drug delivery technology QuSomes. The merger is expected to help TransEnterix enhance its ability to commercialize flexible minimally invasive surgical technologies. Joseph Slattery, who joined the company recently, is expected to help in development and commercialization of SurgiBot as he has relevant experience in medical technology companies. However, it is important to remember that the potential of the merger will be realized only over time. The positive results will take time to get reflected in the top or the bottom-line. Since the stock has already appreciated significantly over the past 7-8 months, it is good to remain a bit cautious. However, the power Frost's support should not be ignored, and it is possible that the stock starts another leg of uptrend.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences